Literature DB >> 23460609

Critical role for mouse marginal zone B cells in PF4/heparin antibody production.

Yongwei Zheng1, Mei Yu, Andrew Podd, Liudi Yuan, Debra K Newman, Renren Wen, Gowthami Arepally, Demin Wang.   

Abstract

Heparin-induced thrombocytopenia (HIT) is an immune-mediated disorder that can cause fatal arterial or venous thrombosis/thromboembolism. Immune complexes consisting of platelet factor 4 (PF4), heparin, and PF4/heparin-reactive antibodies are central to the pathogenesis of HIT. However, the B-cell origin of HIT antibody production is not known. Here, we show that anti-PF4/heparin antibodies are readily generated in wild-type mice on challenge with PF4/heparin complexes, and that antibody production is severely impaired in B-cell-specific Notch2-deficient mice that lack marginal zone (MZ) B cells. As expected, Notch2-deficient mice responded normally to challenge with T-cell-dependent antigen nitrophenyl-chicken γ globulin but not to the T-cell-independent antigen trinitrophenyl-Ficoll. In addition, wild-type, but not Notch2-deficient, B cells plus B-cell-depleted wild-type splenocytes adoptively transferred into B-cell-deficient μMT mice responded to PF4/heparin complex challenge. PF4/heparin-specific antibodies produced by wild-type mice were IgG2b and IgG3 isotypes. An in vitro class-switching assay showed that MZ B cells were capable of producing antibodies of IgG2b and IgG3 isotypes. Lastly, MZ, but not follicular, B cells adoptively transferred into B-cell-deficient μMT mice responded to PF4/heparin complex challenge by producing PF4/heparin-specific antibodies of IgG2b and IgG3 isotypes. Taken together, these data demonstrate that MZ B cells are critical for PF4/heparin-specific antibody production.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23460609      PMCID: PMC3637017          DOI: 10.1182/blood-2013-01-477091

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  Notch2 is preferentially expressed in mature B cells and indispensable for marginal zone B lineage development.

Authors:  Toshiki Saito; Shigeru Chiba; Motoshi Ichikawa; Atsushi Kunisato; Takashi Asai; Kiyoshi Shimizu; Tomoyuki Yamaguchi; Go Yamamoto; Sachiko Seo; Keiki Kumano; Etsuko Nakagami-Yamaguchi; Yoshio Hamada; Shinichi Aizawa; Hisamaru Hirai
Journal:  Immunity       Date:  2003-05       Impact factor: 31.745

2.  Activation of platelets by sera containing IgG1 heparin-dependent antibodies: an explanation for the predominance of the Fc gammaRIIa "low responder" (his131) gene in patients with heparin-induced thrombocytopenia.

Authors:  G A Denomme; T E Warkentin; P Horsewood; J A Sheppard; M N Warner; J G Kelton
Journal:  J Lab Clin Med       Date:  1997-09

3.  Fatal effect of re-exposure to heparin after previous heparin-associated thrombocytopenia and thrombosis.

Authors:  Y Gruel; M Lang; L Darnige; G Pacouret; X Dreyfus; J Leroy; B Charbonnier
Journal:  Lancet       Date:  1990-10-27       Impact factor: 79.321

4.  IgMhighCD21high lymphocytes enriched in the splenic marginal zone generate effector cells more rapidly than the bulk of follicular B cells.

Authors:  A M Oliver; F Martin; J F Kearney
Journal:  J Immunol       Date:  1999-06-15       Impact factor: 5.422

5.  Complexes of heparin and platelet factor 4 specifically stimulate T cells from patients with heparin-induced thrombocytopenia/thrombosis.

Authors:  S Bacsi; R De Palma; G P Visentin; J Gorski; R H Aster
Journal:  Blood       Date:  1999-07-01       Impact factor: 22.113

6.  Characterization of the humoral immune response in heparin-induced thrombocytopenia.

Authors:  J S Suh; M I Malik; R H Aster; G P Visentin
Journal:  Am J Hematol       Date:  1997-03       Impact factor: 10.047

Review 7.  Heparin-induced thrombocytopenia: a ten-year retrospective.

Authors:  T E Warkentin
Journal:  Annu Rev Med       Date:  1999       Impact factor: 13.739

8.  Benefit and risk of heparin for maintaining peripheral venous catheters in neonates: a placebo-controlled trial.

Authors:  Anne Friederike Klenner; Christoph Fusch; A Rakow; Ingrid Kadow; Elke Beyersdorff; Petra Eichler; Kathrin Wander; Theresia Lietz; Andreas Greinacher
Journal:  J Pediatr       Date:  2003-12       Impact factor: 4.406

9.  Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin:platelet factor 4 complexes.

Authors:  G P Visentin; M Malik; K A Cyganiak; R H Aster
Journal:  J Lab Clin Med       Date:  1996-10

10.  Selective increases in antibody isotypes and immunoglobulin G subclass responses to secreted antigens in tuberculosis patients and healthy household contacts of the patients.

Authors:  R Hussain; G Dawood; N Abrar; Z Toossi; A Minai; M Dojki; J J Ellner
Journal:  Clin Diagn Lab Immunol       Date:  1995-11
View more
  16 in total

1.  Critical role of CD4 T cells in PF4/heparin antibody production in mice.

Authors:  Yongwei Zheng; Mei Yu; Anand Padmanabhan; Richard H Aster; Liudi Yuan; Renren Wen; Demin Wang
Journal:  Blood       Date:  2015-01-16       Impact factor: 22.113

2.  Pyoderma gangrenosum-like skin changes after subcutaneous administration of low molecular weight heparin.

Authors:  Małgorzata Sobieszczańska; Sławomir Tubek; Ilona Kura
Journal:  Hum Vaccin Immunother       Date:  2014-01-17       Impact factor: 3.452

3.  B-cell tolerance regulates production of antibodies causing heparin-induced thrombocytopenia.

Authors:  Yongwei Zheng; Alexander W Wang; Mei Yu; Anand Padmanabhan; Benjamin E Tourdot; Debra K Newman; Gilbert C White; Richard H Aster; Renren Wen; Demin Wang
Journal:  Blood       Date:  2013-12-19       Impact factor: 22.113

Review 4.  Heparin-induced thrombocytopenia.

Authors:  Gowthami M Arepally
Journal:  Blood       Date:  2017-04-17       Impact factor: 22.113

5.  Mechanical prophylaxis is a heparin-independent risk for anti-platelet factor 4/heparin antibody formation after orthopedic surgery.

Authors:  Seiji Bito; Shigeki Miyata; Kiyoshi Migita; Mashio Nakamura; Kazuhito Shinohara; Tomotaro Sato; Takeharu Tonai; Motoyuki Shimizu; Yasuhiro Shibata; Kazuhiko Kishi; Chikara Kubota; Shinnosuke Nakahara; Toshihito Mori; Kazuo Ikeda; Shusuke Ota; Takeshi Minamizaki; Shigeru Yamada; Naofumi Shiota; Masataka Kamei; Satoru Motokawa
Journal:  Blood       Date:  2015-12-09       Impact factor: 22.113

Review 6.  Immune pathogenesis of heparin-induced thrombocytopenia.

Authors:  Sanjay Khandelwal; Gowthami M Arepally
Journal:  Thromb Haemost       Date:  2016-07-28       Impact factor: 5.249

Review 7.  Advances in the pathophysiology and treatment of heparin-induced thrombocytopenia.

Authors:  Steven E McKenzie; Bruce S Sachais
Journal:  Curr Opin Hematol       Date:  2014-09       Impact factor: 3.284

8.  Regulatory T Cells Control PF4/Heparin Antibody Production in Mice.

Authors:  Yongwei Zheng; Wen Zhu; Dipica Haribhai; Calvin B Williams; Richard H Aster; Renren Wen; Demin Wang
Journal:  J Immunol       Date:  2019-08-30       Impact factor: 5.422

9.  Influence of Human Leukocyte Antigen (HLA) Alleles and Killer Cell Immunoglobulin-Like Receptors (KIR) Types on Heparin-Induced Thrombocytopenia (HIT).

Authors:  Jason H Karnes; Christian M Shaffer; Robert Cronin; Lisa Bastarache; Silvana Gaudieri; Ian James; Rebecca Pavlos; Heidi E Steiner; Jonathan D Mosley; Simon Mallal; Joshua C Denny; Elizabeth J Phillips; Dan M Roden
Journal:  Pharmacotherapy       Date:  2017-09-04       Impact factor: 4.705

10.  Polyreactive IgM initiates complement activation by PF4/heparin complexes through the classical pathway.

Authors:  Sanjay Khandelwal; Joann Ravi; Lubica Rauova; Alexandra Johnson; Grace M Lee; Jennifer B Gilner; Sreenivasulu Gunti; Abner L Notkins; Maragatha Kuchibhatla; Michael Frank; Mortimer Poncz; Douglas B Cines; Gowthami M Arepally
Journal:  Blood       Date:  2018-10-11       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.